Puma Biotechnology, Inc.
A biopharmaceutical company based in Los Angeles that develops and sells cancer treatments, best known for its breast-cancer drug Nerlynx, a pill given to adults with HER2-positive breast cancer to help stop the disease from returning. It was founded in 2010 by Alan Auerbach, the same entrepreneur behind the earlier Cougar Biotechnology, whose big-cat naming theme it kept: puma and cougar are simply two names for the same mountain lion, and the drug itself was licensed from Pfizer in 2011.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| BlackRock, Inc. | 13G/APassive | 5.6% | 2.78M | Apr 17, 2025 |
| Anders Hove | 13G/APassive | 8% | 3.94M | Feb 14, 2025 |
| ACORN BIOVENTURES 2, L.P. | 13G/APassive | 4.7% | 2.29M | Feb 14, 2025 |
| Acorn Capital Advisors GP 2, LLC | 13G/APassive | 4.7% | 285.2K | Feb 14, 2025 |
| ACORN BIOVENTURES, L.P. | 13G/APassive | 3.3% | 1.65M | Feb 14, 2025 |
| ACORN CAPITAL ADVISORS GP, LLC | 13G/APassive | 3.3% | 1.65M | Feb 14, 2025 |
| Frazier Life Sciences Public Fund, L.P. | 13G/APassive | 0% | 0 | Feb 14, 2025 |
| FHMLSP, L.P. | 13G/APassive | 0% | 0 | Feb 14, 2025 |
| FHMLSP, L.L.C. | 13G/APassive | 0% | 0 | Feb 14, 2025 |